Adherence to Potassium Citrate, Changes in 24-hour Stone Risk Parameters, and Recurrent Kidney Stone Events
Authors:
Open Access
- 3 March 2026
- journal article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (7) , 1625-1632
Abstract
Background: Patient adherence limits the effectiveness of preventive pharmacologic therapy (PPT) for urinary stone disease (USD), highlighting the need for accurate adherence monitoring. We assessed associations between potassium citrate adherence measures, changes in 24-hour urine parameters, and the risk of recurrent stone events. Methods: In this retrospective cohort study, we identified adults enrolled in Medicare with USD, a baseline 24-hour urine collection (2010-2019), hypocitraturia or low urine pH, a prescription for potassium citrate monotherapy, and a follow-up urine collection. We defined two adherence measures: (1) percentage of days covered (PDC) using pharmacy claims and (2) change in urinary potassium between baseline and follow-up divided by medication dose (ΔK/dose). We assessed the association of these measures with changes in urinary citrate and pH using analysis of covariance, and the association between adherence and recurrent stone events using Cox models. Results: Among 793 patients meeting study criteria, 504 (63.6%) were adherent based on pharmacy claims (PDC≥80%) and 389 (49.1%) based on ΔK/dose≥0.5. Compared to PDC≥80%, ΔK/dose≥0.5 had a stronger association with change in urinary citrate ( p p <0.001). Compared to PDC≥80%, patients with PDC<80% had a higher risk of recurrent stone events (hazard ratio [HR] 1.431; 95% confidence interval [CI], 1.049-1.952), whereas ΔK/dose was not statistically significantly associated with recurrent stone events (HR 1.032; 95% CI, 0.740-1.439). Conclusions: There are clinically meaningful differences in potassium citrate adherence measures. ΔK/dose was more strongly associated with the change in urinary citrate and pH. However, only PDC was significantly associated with recurrent stone events.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK121709)
- National Institute of Diabetes and Digestive and Kidney Diseases (1R01DK121709)
This publication has 16 references indexed in Scilit:
- Beneficial Impact of Follow-Up 24-Hour Urine Testing on Adherence to Pharmacological Therapy for Kidney Stone PreventionJU Open Plus, 2024
- Real-World Effectiveness of Preventive Pharmacological Therapy in Patients With Urolithiasis: A Retrospective Cohort StudyAmerican Journal of Kidney Diseases, 2024
- Alkali Citrate Content of Common Over-the-Counter and Medical Food SupplementsJournal of Endourology, 2023
- White coat adherence effect on glucose control in adult individuals with diabetesDiabetes Research and Clinical Practice, 2020
- Factors Associated With Preventive Pharmacological Therapy Adherence Among Patients With Kidney StonesUrology, 2016
- Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney StonesJournal of Urology, 2016
- Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasisUrolithiasis, 2015
- Self-report measures of medication adherence behavior: recommendations on optimal useTranslational Behavioral Medicine, 2015
- Medical Management of Kidney Stones: AUA GuidelineJournal of Urology, 2014
- White Coat Adherence over the First Year of Therapy in Pediatric EpilepsyThe Journal of Pediatrics, 2012